Security key
04272N102
ArriVent BioPharma, Inc. - COMMON STOCK (AVBP)
CUSIP: 04272N102
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 33,625,800
- Total 13F value
- $732,036,140
- Share change
- +4,550,326
- SEC-reported price per share
- $21.77
- Number of holders
- 96
- Value change
- +$99,572,817
- Number of buys
- 49
- Number of sells
- 38
- Shares outstanding
- 44,354,880
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
96
Top holders
10
AVBP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
ArriVent BioPharma, Inc. SEC filings
ArriVent BioPharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 04272N102
Recent filing periods:
Ownership snapshot
Top reported holders of AVBP - ArriVent BioPharma, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
SUVRETTA CAPITAL MANAGEME...
Disclosed value leader
HHLR ADVISORS, LTD.
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
3/4/5
Lead comparable stake: 9.9%
13D/G row: SUVRETTA CAPITAL MANAGEMENT, LLC
Showing 1-6 of 15 holder rows.
Quick read
SUVRETTA CAPITAL MANAGEMENT, LLC leads the comparable SEC ownership view at 9.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens SUVRETTA CAPITAL MANAGEMENT, LLC's linked filing trail.
Comparable ownership
Top 5
SUVRETTA CAPITAL MANAGEMENT, LLC
9.9%
Novo Holdings A/S
4.9%
HHLR ADVISORS, LTD.
10%
ORBIMED ADVISORS LLC
6.8%
BlackRock, Inc.
4.8%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
9.9%
|
$75,183,720
3,412,788 shares
|
$0 | 30 Jun 2025 |
| Novo Holdings A/S |
13F
13D/G
Company
|
4.9%
from 13D/G
|
$34,615,906
1,872,142 shares
|
— | 31 Mar 2025 |
| HHLR ADVISORS, LTD. |
13F
Company
|
10%
|
$82,921,585
4,484,672 shares
|
— | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13F
3/4/5
Company · Director, 10%+ Owner
|
6.8%
|
$55,975,295
3,027,328 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
4.8%
|
$39,564,682
2,139,788 shares
|
— | 31 Mar 2025 |
| FMR LLC |
13F
Company
|
4.7%
|
$38,434,405
2,078,659 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
96
Shares
33,625,800
Rows available
96
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
82
Q2 2025 holders
96
Holder diff
14
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend